Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

NCT03684785 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

57

Enrollment

INDUSTRY

Sponsor class

Stopped The study was canceled for administrative reasons.

Conditions

Advanced or Metastatic Merkel Cell Carcinoma
Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
Advanced or Metastatic Melanoma
Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
Advanced or Metastatic Solid Tumors

Interventions

DRUG: Cavrotolimod
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Cemiplimab
DRUG: Cavrotolimod

Sponsor

Exicure, Inc.